Biotinylated Human LYPD1 / PHTS Protein, His,Avitag™

Cat. No. / Size
Price
Availability
Qty
LY1-H82E6-25ug
$360.00
In Stock - Delivery in 1-2 business days
LY1-H82E6-200ug
$1,420.00
In Stock - Delivery in 1-2 business days
LY1-H82E6
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

LYPD1, Ly6/PLAUR domain-containing protein 1, FLJ41033, LY6/PLAUR domain containing 1, LYPDC1, PHTS, Putative HeLa tumor suppressor

Source

Biotinylated Human LYPD1 Protein, His,Avitag (LY1-H82E6) is expressed from human 293 cells (HEK293). It contains AA Leu 21 - Gly 115 (Accession # Q8N2G4-1).

Molecular Characterization

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 14.1 kDa. The protein migrates as 18-22 kDa and 35-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Labeling

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Protein Ratio

Passed as determined by the SABA assay / HABA assay / binding ELISA.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Background

Believed to act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro increases receptor desensitization and decreases affinity for ACh of alpha-4:beta-2-containing nAChRs. May play a role in the intracellular trafficking of alpha-4:beta-2 and alpha-7-containing nAChRs and may inhibit their expression at the cell surface. May be involved in the control of anxiety.